Interius BioTherapeutics Announces Regulatory Approval to Expand Phase 1 Clinical Trial of INT2104 into Europe January 8, 2025
University of Pennsylvania gene therapy spinout Interius BioTherapeutics doses patient, achieves CAR therapy first November 4, 2024
Interius BioTherapeutics Doses First Patient with in vivo Chimeric Antigen Receptor (CAR) Gene Therapy for B-cell Malignancies October 23, 2024
